RARE
Ultragenyx Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.78
−2.44%Year over year
Reported trailing growth
- Revenue
- +17.5%
- EBITDA
- -8.7%
- EBIT
- -4.7%
- EPS
- -5.6%
- Free cash flow
- -14.5%
- Operating cash flow
- -15.2%
Forward estimates
Based on analyst estimates
- Revenue
- +29.4%
- EBITDA
- +84.8%
- EPS
- +66.1%
Three-year CAGR
- Revenue
- +22.8%
- EBITDA
- -1.1%
- EBIT
- +0.2%
- Net income
- -1.0%
- EPS
- +7.3%
- Free cash flow
- -11.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026